A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
SNTS has been hampered primarily by a patent challenge by Par Pharm. and the stock took a huge hit when this claim came out primarily for two reasons. 1) CEO had stopped giving guidance on a call a few days before and 2) market thought that perhaps the patent challenge would further hamper the cash flow situation at SNTS. Realistically, this suit will probably be settled or won by SNTS. SNTS should reach profitability in Q4, however, the market is overlooking the two major deals SNTS has signed with Glaxo (for foreign distribution) and Schering for OTC distribution. Both companies are comfortable with the patents as should you be. I look for a volatile rocky ride from here...but up it should be. Cheers.